Why Did Piper Sandler Give Intra-Cellular Therapies Inc (ITCI) Stock Overweight Rating?
Intra-Cellular Therapies Inc (ITCI) stock saw a modest uptick, ending the day at $126.5 which represents a slight increase of $0.30 or 0.24% from the prior close of $126.2. The stock opened at $126.64 and touched a low of $126.
Piper Sandler adjusted its price target on City Holding (NASDAQ:CHCO) shares, bringing it down to $125 from the previous $135 while maintaining a Neutral rating. The $1.75 billion regional bank, ...
That's changed: Lyons is acknowledged heir apparent at a giant fintech where he'll become CEO by July at the latest.
Piper Sandler reiterated an Overweight rating and $670 price target on Meta Platforms (META) after CEO Mark Zuckerberg said in a Facebook post ...
Tesla remains the “top buy-and-hold” stock for analysts at Piper Sandler, who massively raised their price target for the ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 14.59% ...
In a report released today, Arvind Ramnani from Piper Sandler maintained a Hold rating on PayPal Holdings (PYPL – Research Report), with a ...
Salesforce shows potential for growth with dominant market share and AI-driven interest from Agentforce, according to Piper ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Piper Sandler analyst Michael Lavery maintained a Buy rating on PepsiCo (PEP – Research Report) today and set a price target of $171.00. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback